Researcher:
Askeroğlu, Mehmet Orbay

Profile Picture
ORCID

Job Title

Other

First Name

Mehmet Orbay

Last Name

Askeroğlu

Name

Name Variants

Askeroğlu, Mehmet Orbay

Email Address

Birth Date

Filters

20231

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.1db68c31-af8c-4b91-b87e-7aedc2185600

Search Results

Now showing 1 - 1 of 1
  • Placeholder
    PublicationMetadata only
    Frameless hypofractionated gamma knife radiosurgery for residual or recurrent craniopharyngioma
    (Lippincott Williams and Wilkins (LWW), 2023) N/A; Samancı, Mustafa Yavuz; Essibayi, Muhammed Amir; Askeroğlu, Mehmet Orbay; Budak, Mustafa; Karaköse, Fatih; Peker, Selçuk; Faculty Member; Other; Other; Other; Other; Faculty Member; School of Medicine; N/A; N/A; N/A; N/A; School of Medicine; Koç University Hospital; 275252; N/A; N/A; N/A; N/A; 11480
    Background: The management of craniopharyngiomas is challenging, usually requiring multidisciplinary care. Gamma Knife radiosurgery (GKRS) is an essential technique for residual/recurrent craniopharyngiomas. Objective: To evaluate the efficacy of frameless hypofractionated GKRS (hfGKRS) for craniopharyngioma and factors which affect tumor control and complications. Methods: This retrospective study involved 24 patients managed with hfGKRS. Clinical and radiological data, tumor characteristics, and procedural details were analyzed. Results: There were 15 (62.5%) female patients. The median age was 38.5 years (range, 3-66 years). The mean tumor volume was 2.4 (1.93) cm3, with a mean solid volume of 1.6 (1.75) cm3. The median marginal dose was 20 Gy (range, 18-25 Gy) delivered in a median of 5 fractions (range, 3-5). During a median radiological follow-up of 23.5 months (range, 12-50 months), tumor progression was noted in 5 (20.8%) patients. The 2-year and 4-year progression-free survival were 81.8% and 61.4%, respectively. No deaths were identified at a median clinical follow-up of 31.3 months (range, 12-54 months). Visual deficits attributable to progression were noted in 3 (12.5%) patients with pre-GKRS visual field defects. An additional 4 (16.7%) patients with pre-GKRS visual deficit developed new minor visual field defects. Four (16.7%) patients showed improvement of vision after GKRS. There were no new-onset post-GKRS hormonal deficits. Conclusion: The management of craniopharyngioma requires a multidisciplinary approach, and irradiation represents effective treatment option for residual/recurrent tumors after surgery. To the best of our knowledge, this is the first study that addresses the efficacy of frameless hfGKRS in managing craniopharyngiomas over sufficient follow-up.